| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-89 |
Sentence |
denotes |
PAI-1 gain-of-function genotype, factors increasing PAI-1 levels, and airway obstruction: |
| T2 |
90-109 |
Sentence |
denotes |
The GALA II Cohort. |
| T3 |
110-262 |
Sentence |
denotes |
BACKGROUND: PAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma. |
| T4 |
263-273 |
Sentence |
denotes |
OBJECTIVE: |
| T5 |
274-560 |
Sentence |
denotes |
We sought to determine whether the association of a gain-of-function polymorphism in plasminogen activator inhibitor-1 (PAI-1) with airway obstruction is modified by asthma status, and whether any genotype effect persists after accounting for common exposures that increase PAI-1 level. |
| T6 |
561-569 |
Sentence |
denotes |
METHODS: |
| T7 |
570-677 |
Sentence |
denotes |
We studied 2070 Latino children (8-21y) with genotypic and pulmonary function data from the GALA II cohort. |
| T8 |
678-810 |
Sentence |
denotes |
We estimated the relationship of the PAI-1 risk allele with FEV1/FVC by multivariate linear regression, stratified by asthma status. |
| T9 |
811-949 |
Sentence |
denotes |
We examined the association of the polymorphism with asthma and airway obstruction within asthmatics via multivariate logistic regression. |
| T10 |
950-1030 |
Sentence |
denotes |
We replicated associations in the SAPPHIRE cohort of African Americans (n=1056). |
| T11 |
1031-1134 |
Sentence |
denotes |
Secondary analysis included the effect of the at-risk polymorphism on postbronchodilator lung function. |
| T12 |
1135-1143 |
Sentence |
denotes |
RESULTS: |
| T13 |
1144-1239 |
Sentence |
denotes |
There was an interaction between asthma status and the PAI-1 polymorphism on FEV1 /FVC (P=.03). |
| T14 |
1240-1407 |
Sentence |
denotes |
The gain-of-function variants, genotypes (AA/AG), were associated with lower FEV1 /FVC in subjects with asthma (β=-1.25, CI: -2.14,-0.35, P=.006), but not in controls. |
| T15 |
1408-1493 |
Sentence |
denotes |
Subjects with asthma and the AA/AG genotypes had a 5% decrease in FEV1 /FVC (P<.001). |
| T16 |
1494-1633 |
Sentence |
denotes |
In asthmatics, the risk genotype (AA/AG) was associated with a 39% increase in risk of clinically relevant airway obstruction (OR=1.39, CI: |
| T17 |
1634-1653 |
Sentence |
denotes |
1.01, 1.92, P=.04). |
| T18 |
1654-1769 |
Sentence |
denotes |
These associations persisted after exclusion of factors that increase PAI-1 including tobacco exposure and obesity. |
| T19 |
1770-1805 |
Sentence |
denotes |
CONCLUSIONS AND CLINICAL RELEVANCE: |
| T20 |
1806-1906 |
Sentence |
denotes |
The decrease in the FEV1 /FVC ratio associated with the risk genotype was modified by asthma status. |
| T21 |
1907-1991 |
Sentence |
denotes |
The genotype increased the odds of airway obstruction by 75% within asthmatics only. |
| T22 |
1992-2170 |
Sentence |
denotes |
As exposures known to increase PAI-1 levels did not mitigate this association, PAI-1 may contribute to airway obstruction in the context of chronic asthmatic airway inflammation. |
| T1 |
0-89 |
Sentence |
denotes |
PAI-1 gain-of-function genotype, factors increasing PAI-1 levels, and airway obstruction: |
| T2 |
90-109 |
Sentence |
denotes |
The GALA II Cohort. |
| T3 |
110-262 |
Sentence |
denotes |
BACKGROUND: PAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma. |
| T4 |
263-273 |
Sentence |
denotes |
OBJECTIVE: |
| T5 |
274-560 |
Sentence |
denotes |
We sought to determine whether the association of a gain-of-function polymorphism in plasminogen activator inhibitor-1 (PAI-1) with airway obstruction is modified by asthma status, and whether any genotype effect persists after accounting for common exposures that increase PAI-1 level. |
| T6 |
561-569 |
Sentence |
denotes |
METHODS: |
| T7 |
570-677 |
Sentence |
denotes |
We studied 2070 Latino children (8-21y) with genotypic and pulmonary function data from the GALA II cohort. |
| T8 |
678-810 |
Sentence |
denotes |
We estimated the relationship of the PAI-1 risk allele with FEV1/FVC by multivariate linear regression, stratified by asthma status. |
| T9 |
811-949 |
Sentence |
denotes |
We examined the association of the polymorphism with asthma and airway obstruction within asthmatics via multivariate logistic regression. |
| T10 |
950-1030 |
Sentence |
denotes |
We replicated associations in the SAPPHIRE cohort of African Americans (n=1056). |
| T11 |
1031-1134 |
Sentence |
denotes |
Secondary analysis included the effect of the at-risk polymorphism on postbronchodilator lung function. |
| T12 |
1135-1143 |
Sentence |
denotes |
RESULTS: |
| T13 |
1144-1239 |
Sentence |
denotes |
There was an interaction between asthma status and the PAI-1 polymorphism on FEV1 /FVC (P=.03). |
| T14 |
1240-1407 |
Sentence |
denotes |
The gain-of-function variants, genotypes (AA/AG), were associated with lower FEV1 /FVC in subjects with asthma (β=-1.25, CI: -2.14,-0.35, P=.006), but not in controls. |
| T15 |
1408-1493 |
Sentence |
denotes |
Subjects with asthma and the AA/AG genotypes had a 5% decrease in FEV1 /FVC (P<.001). |
| T16 |
1494-1633 |
Sentence |
denotes |
In asthmatics, the risk genotype (AA/AG) was associated with a 39% increase in risk of clinically relevant airway obstruction (OR=1.39, CI: |
| T17 |
1634-1653 |
Sentence |
denotes |
1.01, 1.92, P=.04). |
| T18 |
1654-1769 |
Sentence |
denotes |
These associations persisted after exclusion of factors that increase PAI-1 including tobacco exposure and obesity. |
| T19 |
1770-1805 |
Sentence |
denotes |
CONCLUSIONS AND CLINICAL RELEVANCE: |
| T20 |
1806-1906 |
Sentence |
denotes |
The decrease in the FEV1 /FVC ratio associated with the risk genotype was modified by asthma status. |
| T21 |
1907-1991 |
Sentence |
denotes |
The genotype increased the odds of airway obstruction by 75% within asthmatics only. |
| T22 |
1992-2170 |
Sentence |
denotes |
As exposures known to increase PAI-1 levels did not mitigate this association, PAI-1 may contribute to airway obstruction in the context of chronic asthmatic airway inflammation. |